# Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

> **NCT04913337** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 179 (estimated)

## Conditions studied

- Mesothelioma
- Glioblastoma
- Renal Cell Carcinoma
- Non Small Cell Lung Cancer
- Melanoma
- Pancreatic Ductal Adenocarcinoma
- Gastric Cancer
- Squamous Cell Carcinoma of Head and Neck
- Cholangiocarcinoma
- Breast Cancer
- Ovarian Cancer
- Cervical Cancer
- Endocervical Cancer
- Colorectal Cancer
- Esophageal Cancer

## Interventions

- **DRUG:** NGM707
- **DRUG:** NGM707 plus pembrolizumab (KEYTRUDA®)
- **DRUG:** NGM707 plus pembrolizumab (KEYTRUDA®)
- **DRUG:** NGM707 plus pembrolizumab (KEYTRUDA®)
- **DRUG:** NGM707 plus pembrolizumab (KEYTRUDA®)
- **DRUG:** NGM707
- **DRUG:** NGM707
- **DRUG:** NGM707

## Key facts

- **NCT ID:** NCT04913337
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-09
- **Primary completion:** 2025-02
- **Final completion:** 2025-07
- **Target enrollment:** 179 (ESTIMATED)
- **Last updated:** 2024-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913337, "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04913337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*